ABVX: ABIVAX Société Anonyme - Summary | Jitta

ABIVAX Société Anonyme

FRA:ABVX

Price
€77.15
Loss Chance
58.7%
0.66JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (16)
Recent Business Performance (11)
Financial Strength (40)
Return to Shareholders (0)
Competitive Advantage (20)
Jitta Signs
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 57.84% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.66
100.00%
4.40
54.40%
2.92
221.43%
Pharmaceuticals
3.28
100.00%
3.35
100.00%
0.93
100.00%
COMPANY DESCRIPTION
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.